You are viewing: Rest Of Europe In Vitro Diagnostics (IVD) Quality Control Market analysis

The Rest Of Europe In Vitro Diagnostics (IVD) Quality Control Market was valued at $57.5 Million in 2025 and projected to reach to $71.3 Million by 2030, representing a compound annual growth rate of CAGR 4.4%. Rest of Europe's IVD Quality Control Market is positioned for steady growth as healthcare systems across the region prioritize diagnostic accuracy and regulatory compliance.

Rest Of Europe In Vitro Diagnostics (IVD) Quality Control Market Trends and Insights

  • Latin America's IVD quality control sector is experiencing steady growth driven by increasing regulatory compliance requirements, rising diagnostic testing volumes, and expanding laboratory infrastructure across the region.
  • In Latin America, healthcare modernization initiatives and heightened focus on diagnostic accuracy are propelling demand for robust quality control solutions. Latin America's market growth is supported by strengthening healthcare systems and growing awareness of quality assurance in clinical diagnostics.
  • The region's IVD quality control market reflects Latin America's commitment to meeting international standards while addressing local healthcare challenges.
  • Between 2025 and 2030, Latin America is expected to see accelerated adoption of advanced quality control technologies as laboratories invest in compliance and operational excellence..

Key Market Statistics

  • CAGR (2025-2030) CAGR 4.4%
  • Market Size, 2025 ~USD 57.5 Million
  • Forecast, 2030 ~USD 71.3 Million
  • Country Rest Of Europe

Rest Of Europe In Vitro Diagnostics (IVD) Quality Control Market Overview

Market Valuation :

Rest of Europe's IVD Quality Control Market is valued at USD 57.5 million in 2025, with steady expansion anticipated through 2030 as regulatory frameworks strengthen across non-major European markets.

Growth Trajectory :

The region demonstrates a CAGR of 4.4% from 2025 to 2030, reaching USD 71.3 million by forecast end, reflecting moderate but consistent market maturation driven by compliance demands and diagnostic infrastructure development.

Regulatory Drivers :

Increasing harmonization of IVD regulations across Rest of Europe, including IVDR compliance requirements, is propelling demand for quality control solutions among diagnostic laboratories and manufacturers.

Market Dynamics :

Rising diagnostic testing volumes, expanding healthcare expenditures, and growing adoption of advanced quality assurance protocols are key factors supporting sustainable growth in Rest of Europe's IVD quality control sector.

Rest Of Europe In Vitro Diagnostics (IVD) Quality Control Market Dynamics

  • The market's 4.4% CAGR reflects increasing investments in laboratory infrastructure and quality management systems, particularly in emerging European economies seeking to align with EU standards.
  • Diagnostic laboratories and IVD manufacturers are increasingly adopting sophisticated quality control solutions to meet stringent regulatory requirements and ensure product reliability. The forecast period through 2030 will be characterized by gradual market expansion driven by rising healthcare awareness, improved reimbursement policies, and technological advancements in quality control methodologies.
  • Rest of Europe presents significant opportunities for market players offering cost-effective, compliant solutions tailored to regional laboratory needs and regulatory frameworks..

Related Ecosystem

In Vitro Diagnostics

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Dna Microarrays
  • Assay Kits
  • Microarrays
Top Companies
  • ROCHE HOLDINGS AG
  • Thermo Fisher Scientific Inc.
  • Danaher Corporation
  • Abbott Laboratories
  • Biomerieux s.a.

    Medical Devices

    Top Technologies
    • Polymerase Chain Reaction (PCR)
    • Magnetic Resonance Imaging (MRI)
    • Disposable Autoinjectors
    • Pulse Oximeters
    • Blood Pressure Monitors
    Top Companies
    • Medtronic plc
    • Abbott Laboratories
    • Stryker Corporation
    • Becton, Dickinson and Company
    • JOHNSON & JOHNSON

      Key Takeaways

      • Latin America's IVD Quality Control Market is valued at USD 57.5 million in 2025 and will reach USD 71.3 million by 2030.
      • Latin America is experiencing a 4.4% CAGR, driven by regulatory compliance and laboratory modernization initiatives.
      • Latin America's market growth is supported by expanding healthcare infrastructure and increased diagnostic testing demand.
      • Latin America's laboratories are increasingly adopting advanced quality control technologies to meet international standards.

      In Vitro Diagnostics (IVD) Quality Control Market Report Scope

      Report Metric Details
      Base Year 2025
      Fastest Growing Segment MOLECULAR DIAGNOSTICS (Technology)
      Forecast Period 2025–2030
      Growth Rate CAGR of 5.5% from 2025 to 2030
      Largest Segment QUALITY CONTROL PRODUCTS (Product & Service)
      Market Size Base Year (Billions) ~USD 1.65 (2025)
      Revenue Forecast (Billions) ~USD 2.15 (2030)
      Segments Covered Product & Service, Type, Technology, Manufacturer Type, End User

      Rest Of Europe In Vitro Diagnostics (IVD) Quality Control Market Report Segmentation

      5 segment dimensions are covered across the global market.

      By Product & Service

      • Data Management Solutions
      • Quality Assurance Services
      • Quality Control Products

      By Type

      • Independent Controls
      • Instrument-Specific Controls
      • Other Controls
      • Serum/Plasma-Based Controls
      • Urine-Based Controls
      • Whole Blood-Based Controls

      By Technology

      • Clinical Chemistry
      • Coagulation & Hemostasis
      • Hematology
      • Immunoassays
      • Microbiology
      • Molecular Diagnostics
      • Other Technologies

      By Manufacturer Type

      • Original Equipment Manufacturer Controls
      • Third-Party Controls

      By End User

      • Academic & Research Institutes
      • Clinical Laboratories
      • Hospitals
      • Other End Users

      Target Audience

      • IVD Manufacturers : Manufacturers require Rest of Europe-specific market data to develop compliant quality control products, understand regional regulatory requirements, and identify distribution opportunities in emerging European markets.
      • Diagnostic Laboratory Operators : Laboratory managers need insights into quality control market trends and solution providers serving Rest of Europe to optimize their quality assurance protocols and ensure regulatory compliance across their operations.
      • Quality Control Solution Providers : Service providers and software vendors targeting Rest of Europe need detailed market intelligence to position offerings, identify customer segments, and develop region-specific sales and marketing strategies.
      • Healthcare Investors & Consultants : Investment firms and management consultants require Rest of Europe market data to evaluate portfolio opportunities, assess market attractiveness, and guide clients on expansion strategies in the IVD quality control sector.
      • Regulatory & Compliance Officers : Compliance professionals need region-specific regulatory insights and market trends for Rest of Europe to ensure organizational alignment with evolving IVDR requirements and quality control standards.

      Key Companies in the Rest Of Europe In Vitro Diagnostics (IVD) Quality Control Market

      CompanyHQOwnershipStrongest segments
      BIOMERIEUX S.A.FrancePublic CompanyClinical microbiology (VITEK, culture media, ID/AST, BACT/ALERT),Syndromic and molecular diagnostics (BIOFIRE, SPOTFIRE, ARGENE, NUCLISENS),Immunoassays and biomarkers (VIDAS, Hybiome CLIA, sepsis markers),
      CEPHEID INC.United StatesPrivate CompanyGeneXpert instruments and Xpert test cartridges,SmartCycler systems and assays,Collaborative and program-based solutions (e.g., TB, Ebola, USPS BDS),
      IMMUCOR, INC.United StatesPrivate CompanyTransfusion (serology instruments and reagents),Transplant & Molecular (HLA, HEA/HPA typing, Array Imaging System),Platelet-focused and specialty coagulation products,
      DIASORINItalyPublic CompanyImmunodiagnostics – Infectious and Gastrointestinal Diseases,Immunodiagnostics – Endocrinology and Metabolic Disorders,Oncology and Tumor Markers,
      UNILABSSwitzerlandPrivate CompanyCore laboratory testing,Medical imaging services,Pathology and centres of excellence,
      BIO-RAD LABORATORIES, INC.United StatesPublic CompanyClinical Diagnostics,Life Science Research Instruments and Reagents,Other and Services,
      THERMO FISHER SCIENTIFIC, INC.United StatesPublic CompanyLife Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
      ABBOTTUnited StatesPublic CompanyDiagnostic Products (core lab, rapid, molecular, cardiometabolic, drug testing),Medical Devices (cardiovascular, diabetes care, neuromodulation),Nutritional Products (pediatric, adult, infant formula),
      LGC LIMITEDSouth KoreaPublic CompanyEthylene-based synthetic resins (EVA, HDPE, LDPE, LLDPE, POE, metallocene PE, UNIQABLE),Styrene-based resins (ABS, ASA, EPS, PS, SAN),Polycarbonate and polypropylene,
      SIEMENS HEALTHINEERS AGGermanyPublic CompanyImaging,Diagnostics,Varian (Oncology),
      QUIDELORTHO CORPORATIONUnited StatesPublic CompanyLabs (clinical chemistry and immunoassay),Transfusion Medicine,Point of Care (professional and OTC),
      DANAHER CORPORATIONUnited StatesPublic CompanyBiotechnology (bioprocessing and related solutions),Life Sciences (research tools and genomic medicines),Diagnostics (clinical instruments and consumables),
      SYSMEX CORPORATIONJapanPublic CompanyHematology analyzers and reagents (XN-Series, XN-V, ProCyte Dx),Coagulation systems and reagents,Blood gas, electrolyte, and urinalysis analyzers,
      BIO-TECHNE CORPORATIONUnited StatesPublic CompanyProtein Sciences reagents (cytokines, growth factors, antibodies, small molecules, sera, cell selection),Proteomic and protein analysis instruments and immunoassays,Diagnostics products, controls, calibrators, and assays,
      MICROBIX BIOSYSTEMS INC.CanadaPublic CompanyAntigen and test ingredient business,QAPs branded test controls and quality assessment products,DxTM viral transport medium,
      GRIFOLS, S.A.SpainPublic CompanyBiopharma (plasma-derived medicines),Diagnostic,Bio Supplies,

      BIOMERIEUX S.A.

      bioMérieux S.A. is a French public company founded in 1963 that employs 14,894 people. The company operates in the diagnostics and life sciences sector.

      CEPHEID INC.

      Cepheid Inc. is a private company founded in 1996 in the United States with 1,700 employees. The company specializes in molecular diagnostics and infectious disease testing.

      IMMUCOR, INC.

      Immucor, Inc. is a private company founded in 1982 in the United States with 1,125 employees. The company focuses on blood bank and transfusion diagnostics.

      DIASORIN

      DiaSorin is an Italian public company founded in 1968 with 3,242 employees. The company operates in the in vitro diagnostics sector.

      UNILABS

      Unilabs is a private company founded in 1987 in Switzerland with 1,897 employees. The company provides laboratory and diagnostic services.

      BIO-RAD LABORATORIES, INC.

      Bio-Rad Laboratories, Inc. is a public company founded in 1952 in the United States with 7,450 employees. The company develops and manufactures life science research and clinical diagnostics products.

      THERMO FISHER SCIENTIFIC, INC.

      Thermo Fisher Scientific, Inc. is a public company founded in 1956 in the United States with 125,000 employees. The company is a global leader in serving science with laboratory equipment, reagents, and analytical instruments.

      ABBOTT

      Abbott is a public company founded in 1888 in the United States with 115,000 employees. The company operates in diagnostics, medical devices, pharmaceuticals, and nutritional products.

      LGC LIMITED

      LGC Limited is a public company founded in 1947 in South Korea with 14,019 employees. The company provides testing, proficiency testing, and reference materials services.

      SIEMENS HEALTHINEERS AG

      Siemens Healthineers AG is a public company founded in 1896 in Germany with 72,369 employees. The company provides medical imaging, laboratory diagnostics, and point-of-care testing solutions.

      QUIDELORTHO CORPORATION

      QuidelOrtho Corporation is a public company founded in 1979 in the United States with 6,500 employees. The company develops and manufactures rapid diagnostic tests and molecular testing solutions.

      DANAHER CORPORATION

      Danaher Corporation is a public company founded in 1969 in the United States with 59,000 employees. The company operates across diagnostics, life sciences, and environmental and applied solutions segments.

      SYSMEX CORPORATION

      Sysmex Corporation is a public company founded in 1968 in Japan with 10,861 employees. The company manufactures hematology analyzers and other in vitro diagnostic systems.

      BIO-TECHNE CORPORATION

      Bio-Techne Corporation is a public company founded in 1976 in the United States with 3,100 employees. The company develops and manufactures life science tools and bioanalytical instruments.

      MICROBIX BIOSYSTEMS INC.

      Microbix Biosystems Inc. is a public company founded in 1988 in Canada with 100 employees. The company produces quality control materials and reference standards for diagnostics.

      GRIFOLS, S.A.

      Grifols, S.A. is a public company founded in 1909 in Spain with 25,000 employees. The company specializes in blood plasma derivatives and diagnostic products.

      Reasons to Buy this Report

      • Regional Market Sizing : Obtain precise valuation data for Rest of Europe's IVD Quality Control Market with detailed 2025-2030 projections, enabling accurate budget allocation and market entry strategies specific to non-major European territories.
      • Regulatory Landscape Intelligence : Understand region-specific IVDR compliance requirements and regulatory drivers shaping demand for quality control solutions, critical for manufacturers and service providers targeting Rest of Europe markets.
      • Growth Opportunity Identification : Identify emerging opportunities within Rest of Europe's 4.4% CAGR growth trajectory, including underserved diagnostic segments and expanding laboratory networks requiring quality control infrastructure investments.
      • Competitive Positioning : Benchmark your offerings against regional market dynamics and competitor strategies in Rest of Europe, enabling differentiated product development and targeted go-to-market approaches for this distinct market segment.
      • Investment Decision Support : Make informed investment and partnership decisions with comprehensive market data on Rest of Europe's IVD quality control sector, including growth drivers, market gaps, and expansion potential through 2030.

      Frequently asked questions

      What is the current market size of IVD Quality Control in Latin America?

      Latin America's IVD Quality Control Market is valued at USD 57.5 million in 2025.

      What is the projected market size for Latin America by 2030?

      Latin America's IVD Quality Control Market is projected to reach USD 71.3 million by 2030.

      What is the CAGR for Latin America's IVD Quality Control Market?

      Latin America's IVD Quality Control Market is growing at a CAGR of 4.4% from 2025 to 2030.

      What factors are driving growth in Latin America's IVD Quality Control Market?

      Latin America's market growth is driven by regulatory compliance requirements, expanding laboratory infrastructure, healthcare modernization, and increased diagnostic testing volumes.

      How does Latin America's IVD Quality Control Market compare to global trends?

      Latin America's 4.4% CAGR is slightly below the global 5.5% CAGR, reflecting regional economic conditions and varying adoption rates of advanced quality control technologies.

      RESEARCH METHODOLOGY

      The study involved major activities in estimating the current market size for the global IVD quality controls market.

      Exhaustive secondary research was done to collect information on the IVD quality controls market. The next step was to validate these findings, assumptions, and sizing estimates with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the IVD quality controls market.

      The four steps involved in estimating the market size are as follows:

      Secondary Research

      In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

      Primary Research

      In the primary research process, various sources from the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as assess prospects.

      The following is a breakdown of the primary respondents:

      In Vitro Diagnostics (IVD) Quality Control Market

      Note 1: Others include sales, marketing, and product managers.

      Note 2: Companies are classified into tiers based on their total revenue. Here’s the breakdown of tiers: Tier 1 = > USD 100 million, tier 2 = USD 10 million to USD 100 million, and tier 3 = < USD 10 million

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      Both the top-down and bottom-up approaches were used to estimate and validate the IVD quality controls market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size included the following:

      In Vitro Diagnostics (IVD) Quality Control Market

      Data Triangulation

      After arriving at the overall market size by applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

      Market Definition

      IVD quality controls are standardized materials used to monitor, evaluate, and ensure the accuracy, reliability, and precision of diagnostic testing processes in clinical laboratories. These controls are designed to mimic patient samples and are produced from human-derived matrices such as serum, plasma, urine, or whole blood. IVD quality controls provide a benchmark for validating test system performance, detecting errors, and ensuring regulatory compliance across diverse diagnostic platforms.

      Stakeholders

      • Senior Management
      • End Users
      • Finance/Procurement Department
      • R&D Department

      Report Objectives

      • To define, describe, segment, and forecast the global IVD quality controls market by product & service, technology, manufacturer type, end user, and region
      • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
      • To analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall IVD quality controls market
      • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
      • To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
      • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies2
      • To track and analyze company developments such as product launches & approvals, partnerships, acquisitions, agreements, and other developments
      • To benchmark players within the IVD quality controls market using the Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offerings
      • To study the impact of AI/Gen AI on the market, along with the macroeconomic outlook for each region

      Get the Full In Vitro Diagnostics (IVD) Quality Control Market Report

      Full forecast, segment splits, and company analysis for all In Vitro Diagnostics (IVD) Quality Control Market.

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      DMCA.com Protection Status